

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

Here you can find the list of abstracts accepted for:

-Stand-up Poster Presentation during Wine & Cheese & Kept on site for both days

- Poster Presentation during Coffee & Lunch Breaks - One day presentation

Each presenter has to stay near his/her poster during coffee & lunch break according the day of his/her presentation.

The participants will go around the different posters.

If you had 2 or 3 posters accepted, you have to change it during the day. Only one panel is allocated by person.

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|------------------------------|---|
| 1 | 1 | Abayomi A. | Results from a training workshop focusing on stigma reduction for Ebola survivors in Monrovia, Liberia 14–16 JAN 2015 |
| 2 | 2 | Gesser A. | Outbreak or epidemic? How obama's language choice transformed the Ebola outbreak into an epidemic |
| 3 | 3 | Grimes D. E. | Who will care for patients during an Ebola outbreak in developed countries: lessons from bioterrorism |
| 4 | 4 | Ikemura T. | Big data bioinformatics for designing therapeutic oligonucleotides fo Ebolaviruses diseases |
| 5 | 5 | Krause G. | Surveillance and outbreak response management system to support the control of the Ebola virus disease (evd) outbreak |

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|------------------------------|---|
| 6 | 6 | McCarthy S. D. S. | Post-exposure treatment with ifn- β and nucleoside analogs inhibit Ebola replication in a rapid screening assay |
| 7 | 7 | Milligan I. | A phase i, randomised, placebo-controlled, observer-blind trial of heterologous prime-boost schedules of ad26 and mva vector vaccines expressing Ebolavirus target proteins: a preliminary data |
| 8 | 8 | Morley D. | Ireland's plan for Ebola viral disease |
| 9 | 9 | Schnierle B. | Assay development and identification of inhibitors of Ebola virus cell entry |
| 10 | 10 | Slegers C. | Current results and next steps for merck rsv-ebov vaccine program |
| 11 | 11 | Taylor E. | Cellular selenoprotein mRNA tethering via antisense interactions with Ebola and HIV-1 mRNAs may impact host selenium biochemistry |
| 12 | 12 | Tramontano E. | Definition of key residues in dsrna recognition of Ebola virus vp35 for drug development |
| 13 | 13 | Wülfroth P | Vascular leak- an underestimated problem in Ebola and other hemorrhagic diseases |

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|------------------------------|---|
| 14 | 14 | Zhang CY. | Small RNA in natural herb inhibits the function of Ebola virus by targeting GP protein in mouse model |
| 15 | Day 1 | Adams N. H. | Development of a User-Focused Assay for Ebola Virus Sample Collection and Detection |
| 16 | Day 1 | Adjogoua E. V. | Introduction of biological surveillance of Ebola virus disease in Ivory Coast |
| 17 | Day 1 | Agwale SM | Construction and evaluation of a highly immunogenic Ebola influenza VLP vaccine candidate |
| 18 | Day 1 | Akinsola H.A. | Ethical obligation to provide care: factors that can hinder or motivate the participation of student nurses in South Africa in caring for Ebola patients in case of a possible outbreak |
| 19 | Day 1 | Ampofo W. | Surveillance for Ebola virus disease (EVD) in Ghana |
| 20 | Day 1 | Bentley E. | Ebolavirus pseudotypes as antigen surrogates for serological studies |
| 21 | Day 1 | Biswas M.H.A | Modeling and control of the spread of Ebola like epidemic: a case study of deadly nipah virus (niv) infection in bangladesh |

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|----------------------------------|--|
| 22 | Day 1 | Boitard A. | EbolaMoDRAD – Ebola Virus: Modern Approaches for developing bedside Rapid Diagnostics |
| 23 | Day 1 | Bonacic Marinovic A. | Timing of Ebola contact tracing intervention and prospects for stopping the outbreak. |
| 24 | Day 1 | Brandao dos Santos Pedrosa P. | Comparison of evolutionary dynamics of zaire Ebolaviruses from the still ongoing westen Africa epidemic and previously described zaire eolaviruses |
| 25 | Day 1 | Chen G. | Engineering of protective synthetic antibodies targeting sudv by phage display |
| 26 | Day 1 | Cnops L. | Laboratory diagnosis of Ebola virus disease in belgium |
| 27 | Day 1 | Cori A. | Contact patterns driving Ebola transmission in west Africa |
| 28 | Day 1 | Cotte J. | Fluid resuscitation in an Ebola treatment unit: a comparison of central and peripheral venous access |
| 29 | Day 1 | Daino G. L. | A new fluorescence assay to measure vp35-dsrna binding activity |

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|------------------------------|--|
| 30 | Day 1 | Diercke M. | How to engage european public health professionals to support the international Ebola response in west Africa |
| 31 | Day 1 | D'Ortenzio E. | Reported incidents in the Ebola crisis management in Guinea, Liberia and Sierra Leone: a systematic review |
| 32 | Day 1 | Dozio E. | Impact of psychological support to people affected by evd outbreak in Liberia |
| 33 | Day 1 | Dupoteau F. | First rapid Ebola test authorized for emergency use combined with real-time digital data capture and management |
| 34 | Day 1 | Ezekiel Adebisi | Human metabolic network modeling: simulation and interpretation of Ebola high throughput data from pathological and drug treated states |
| 35 | Day 1 | Fusco D. | Interferon effectors as a platform for broad-acting antiviral design |
| 36 | Day 1 | Goh B.C. | Development of Antibody-like binders for rapid in-field Ebola infection screening guided by Computer-Aided design and biomolecular simulations |
| 37 | Day 1 | Goumka Mafopa N. | Preliminary data on sero-surveillance and sero-prevalence of Ebola infection in the northern district of sierra leone |

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|------------------------------|---|
| 38 | Day 1 | Hamakubo T. | Protective effect of pentraxin 3 in animal models of sepsis |
| 39 | Day 1 | Harmer A. | Research for health in humanitarian crises: Ebola call projects in focus |
| 40 | Day 1 | Hawley J. | Ebola outbreak in west Africa: factors contributing to the spread of infection and understanding the challenges of reducing transmission |
| 41 | Day 1 | Helson L. | Liposomal curcumin (lipocurctm) and in vitro surrogates for cytokine storm associated with uncontrolled Ebola infection |
| 42 | Day 1 | Hunt L. | Clinical presentation, biochemical and hematological parameters and their association with outcome in patients with Ebola virus disease at Kerry town, Sierra Leone |
| 43 | Day 1 | Janvier F. | Zaire Ebola virus negative results by reAlstar® filovirus screen rt-pcr kit 1.0 in Guinea |
| 44 | Day 1 | Karlas A. | Global identification of host cell factors essential for Ebola virus replication |
| 45 | Day 1 | Kizek | Ebola gp protein fragments and their basic characterisation provided by mass spectrometry, spectroscopy, chromatography and electrochemistry |

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|------------------------------|---|
| 46 | Day 1 | Knott V. | Palliative care in an Ebola setting: challenges from the front line |
| 47 | Day 1 | Krejцова | Beads-based automatic pcr for detection of lentivirus with Ebola gp protein |
| 48 | 17 | Kuehne A. | Differentiating high and low suspect Ebola cases based on clinical presentation and history of contact |
| Day 2 | 18 | Lambe R. | Humoral immunity induced by prime boost vaccination regimen using viral vectored vaccines towards Ebola virus |
| Day 2 | 19 | Le Mercier P. | Ebolavirus molecular biology in viralzone resource |
| Day 2 | 20 | Leendertz F. H. | Interdisciplinarity as a prerequisite to illuminate the zoonotic origins of Ebola epidemics |
| Day 2 | 21 | Luczowiak J. A. | Specific neutralizing response in plasma from convalescent patients of Ebola virus disease against the west Africa makona variant of Ebolavirus |
| Day 2 | 22 | MacDermott N. | A mobile rapid response model to address cluster outbreaks of Ebola virus disease (evd) |

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|------------------------------|--|
| Day 2 | 23 | Madelain V. | Ebola viral dynamics in mice treated with favipiravir |
| Day 2 | 24 | Manda V. | The use of 'zoning' to control Ebola at a mine site in sierra leone |
| Day 2 | 25 | Mbala K. P. | Prompt diagnosis and first characterization of the viruses responsible for the 2014 Ebola viruses outbreak in the democratic republic of congo |
| Day 2 | 26 | Michalek P. | The preparation and characterisation of lentivirus with Ebola gp protein |
| Day 2 | 27 | Moschos S. | Ebolacheck: realising molecular diagnostics at the point of need |
| Day 2 | 28 | Namy O. | Ribosome profiling to explore genome-wide translational modifications in response to Ebola virus infection |
| Day 2 | 29 | Nelson D. | Prototype multi-agent lateral flow immunoassay (lfi) for the detection of lassa virus (lasv), malaria and Ebola virus (ebov) for the point of care detection of endemic infections |
| Day 2 | 30 | Ogbewi K. | Modeling the Nigerian public health competencies in developing responsive public health care systems in early filovirus (Ebola) outbreaks in developing Africa |

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|------------------------------|--|
| Day 2 | 31 | Ouedraogo D.E. | Ebola virus disease: which lessons learnt and which riposte strategies for unreached countries near outbreak areas? |
| Day 2 | 32 | Page M. | Production of serological and rna reference materials for Ebolavirus |
| Day 2 | 33 | Palombi L. | Retention and mortality in an HIV-infected patient cohort in conakry during the Ebola outbreak. Results from the dream (drug resource enahncement against aids and malnutrition) program |
| Day 2 | 34 | Quigley S. | Ebovac: testing the safety and efficacy of a novel prime boost prophylactic vaccine regimen against Ebola virus disease |
| Day 2 | 35 | Rosales-Mendoza S. | Developing epitope-based Ebola vaccines made in plant cells |
| Day 2 | 36 | Rowland M. | Development of prototype filovirus recombinant antigen immunoassays |
| Day 2 | 37 | Santermans E. | Spatiotemporal evolution of Ebola virus disease at sub-national level during the 2014 west Africa epidemic |
| Day 2 | 38 | Semple MG. | Characterisation of post Ebola syndrome |

Targeting Ebola World Congress

May 28-29, 2015 - Institut Pasteur, Paris

Abstracts accepted for Poster Presentation

| DAY 1 - Number of Poster | DAY 2 - Number of Poster | Name of Presenting Author | Title of the Abstract |
|--------------------------------|--------------------------------|------------------------------|---|
| Day 2 | 39 | Strecker T. | European mobile laboratory unit guéckédou, Guinea: field evaluation of capillary blood samples as a new approach for the rapid diagnosis of Ebola virus disease |
| Day 2 | 40 | Verbeek L. | Pilot phase “effo” – efficient by formation - prevention of Ebola |
| Day 2 | 41 | Watson R.J. | Towards a novel rapid loop mediated isothermal amplification diagnostic for Ebola |
| Day 2 | 42 | Wilkie J. J. | Short-range air transportation of Ebola suspect cases: an evidence-based protocol |